Effects of Neoadjuvant Immunochemotherapy on Perioperative Rocuronium Neuromuscular Blockade and Sugammadex Reversal in Elderly Patients with Esophageal Cancer: A Prospective Observational Cohort Study
Drug Design, Development and Therapy · 2026-11 · Volume 20 · 1-17
DOI: 10.2147/dddt.s652441 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Drug Design, Development and Therapy, 2026-11. Verfasst von Halisa Paerhati und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
Neoadjuvant immunochemotherapy (NICT) is increasingly used in elderly patients with esophageal cancer, but its effects on neuromuscular blockade and reversal remain unclear. We evaluated NICT effects on rocuronium-induced blockade and sugammadex reversal in elderly esophagectomy patients.
Methods
This prospective observational cohort study recruited 65 elderly patients (≥ 65 years) undergoing elective esophagectomy at Jiangsu Cancer Hospital; 57 were analyzed (29 NICT, 28 treatment-naive (TN) group). NICT patients received PD-1/PD-L1 inhibitors plus taxanes and platinum; TN patients received no neoadjuvant treatment. Rocuronium 0.6 mg/kg was given as a peripheral intravenous bolus, then infused and titrated by quantitative neuromuscular monitoring. After surgery, when the second train-of-four (TOF) twitch was detectable, both groups received sugammadex 2 mg/kg. The primary outcome was mean consumption rate of rocuronium. Secondary outcomes included rocuronium onset time, times to T1 recovery of 10% and 25%, and recovery index and time to TOF ratio (TOFr) recovery to 90% after sugammadex; adverse events were recorded.
Results
Mean consumption rate of rocuronium was higher with NICT (12.73 ± 2.80 vs 10.54 ± 1.56 μg·kg − 1 ·min − 1 ; mean difference 2.19, 95% CI 0.98– 3.40; P< 0.001; Hedges‘g=0.95, 95% CI 0.40– 1.49). Rocuronium onset was longer (4.18 ± 1.73 vs 3.01 ± 0.99 min; P=0.003), and times to T1 recovery of 10% and 25% were shorter (P=0.001 and P< 0.001). No significant difference was detected in sugammadex-assisted recovery index (P=0.196) or time to TOFr recovery to 90% (P=0.299); however, the study was not powered for these outcomes, and findings were inconclusive. Adverse events were comparable.
Conclusion
In elderly esophagectomy patients, NICT was associated with higher rocuronium requirements, delayed onset, and faster spontaneous recovery, consistent with reduced sensitivity. Its effect on sugammadex reversal remained inconclusive. Quantitative monitoring and individualized titration can manage these changes, but the single-center observational design limits generalization. Infographic with two stacked sections titled, Study protocol and, Key findings & Clinical implications. Study protocol section text: Population: Elderly patients (greater than or equal to 65 y) undergoing esophagectomy. Prospective observational cohort (n equals 57 analyzed). Two groups: NICT (n equals 29) with PD-1 or PD-L1 inhibitor plus taxane plus platinum (neoadjuvant) and TN (n equals 28) with No neoadjuvant treatment. Sequence: Induction, Rocuronium 0.6 mg per kg IV bolus; Maintenance, Continuous infusion titrated by quantitative TOF monitoring; Reversal, Sugammadex 2 mg per kg at reappearance of 2nd TOF twitch. Outcomes: Primary outcome: mean rocuronium consumption rate (microgram times kg superscript minus 1 end superscript times min superscript minus 1 end superscript). Secondary outcomes: onset time, T1 recovery 10 percent /25 percent, sugammadex reversal. Key findings & Clinical implications section text. Key findings: Higher rocuronium consumption in NICT (12.73 vs 10.54 microgram times kg superscript minus 1 end superscript times min superscript minus 1 end superscript P less than 0.001). Delayed rocuronium onset (4.18 vs 3.01 min, P equals 0.003). Faster spontaneous recovery T1 10 percent (P equals 0.001) T1 25 percent (P less than 0.001). Sugammadex reversal: no significant difference (Recovery index P equals 0.196 TOF 90 percent P equals 0.299). Clinical implications: NICT associated with reduced rocuronium sensitivity. Increased requirement plus delayed onset plus faster spontaneous recovery. Quantitative monitoring and individualized titration. To manage altered rocuronium requirements. Effect on sugammadex reversal remains inconclusive. Larger studies warranted.An infographic summarizing a study protocol and key findings on rocuronium in elderly esophagectomy patients.
Zitieren
APA
Paerhati, H., Hu, X., Zhang, M., & Gu, L. (2026). Effects of Neoadjuvant Immunochemotherapy on Perioperative Rocuronium Neuromuscular Blockade and Sugammadex Reversal in Elderly Patients with Esophageal Cancer: A Prospective Observational Cohort Study. Drug Design, Development and Therapy, Volume 20, 1-17. https://doi.org/10.2147/dddt.s652441
Vancouver
Paerhati H, Hu X, Zhang M, Gu L. Effects of Neoadjuvant Immunochemotherapy on Perioperative Rocuronium Neuromuscular Blockade and Sugammadex Reversal in Elderly Patients with Esophageal Cancer: A Prospective Observational Cohort Study. Drug Design, Development and Therapy. 2026;Volume 20:1-17. doi:10.2147/dddt.s652441
BibTeX
@article{Paerhati2026,
author = {Paerhati, Halisa and Hu, Xinyang and Zhang, Minhao and Gu, Lianbing},
title = {Effects of Neoadjuvant Immunochemotherapy on Perioperative Rocuronium Neuromuscular Blockade and Sugammadex Reversal in Elderly Patients with Esophageal Cancer: A Prospective Observational Cohort Study},
journal = {Drug Design, Development and Therapy},
year = {2026},
volume = {Volume 20},
pages = {1--17},
doi = {10.2147/dddt.s652441}
}
EUVIMED